Annexon Biosciences Appoints Bill Young as Chairman and Adds Tom Wiggans to Board of Directors

09:00 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Annexon Biosciences, a biopharmaceutical company pioneering the development of antibodies that inhibit the classical complement pathway to treat neurodegenerative and autoimmune disorders, today announced the appointment ...

Other Sources for this Article

MacDougall Biomedical Communications
Doug MacDougall, 781-235-3060


More From BioPortfolio on "Annexon Biosciences Appoints Bill Young as Chairman and Adds Tom Wiggans to Board of Directors"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...